Clinical Outcomes of the Gore Synthetic Cornea Device

Launched by W.L.GORE & ASSOCIATES · Dec 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new device called the GORE Synthetic Cornea Device, which aims to improve vision for patients with corneal opacity, a condition where the clear surface of the eye becomes cloudy. The study's goal is to see how safe and effective this device is for people who might need a cornea transplant. The trial is currently recruiting participants aged 18 and older, who have a cloudy cornea and certain vision issues. To be eligible, patients must be able to understand the study and agree to follow all directions, including attending follow-up appointments for a year after the surgery.

Participants in this trial can expect to receive the GORE Synthetic Cornea Device and will closely monitor their recovery and vision over the following months. It's important for potential participants to know that there are specific inclusion and exclusion criteria, meaning that not everyone will qualify to join the study. For example, individuals with certain eye conditions, those under 18, or people who have had specific recent eye infections may not be eligible. This trial is a chance to help improve treatment options for corneal opacity, and participants will play an important role in understanding how well this new device works.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Patients must meet all of the following criteria to be eligible to be consented for this study.
• • 1. Patient must be able to comprehend the study requirements and provide written informed consent. Patients must be willing to follow study instructions, agree to comply with all study procedures , and able to return for all scheduled follow-up examinations for 12 months postoperatively (the study duration). The follow-up exams may be extended up to 60 months post operatively if the patient consents to the extension.
• • 2. Male or female patients ≥ 18 years old at the time of consent
• • 3. Physical condition suitable for undergoing surgery, as evidenced by medical history and physical examination provided by a licensed medical provider (primary care physician, nurse practitioner, internal medicine physician etc.)
• • 4. Currently with an opaque cornea (as determined by the investigator) with or without a prior history of failed donor corneal transplantation \[penetrating keratoplasty (PK) or endothelial keratoplasty (EK)\] and loss of corneal clarity
• • 5. Best corrected distance visual acuity of worse than 20/400 in the study eye using Snellen chart
• • 6. Best corrected distance visual acuity of better than 20/200 in the fellow (non-study) eye using Snellen chart
• • 7. Pseudophakia status in the study eye with a stable posterior chamber intraocular lens (IOL) implant centered within the capsular bag or sulcus
• • 8. Corneal thickness measurement in study eye (epithelium to endothelium; central and mid-peripheral/ 3 to 5mm away from center at superior, inferior, nasal and temporal quadrants) with each measurement between 700um - 900um, measured using ultrasound (US) pachymetry. If one or more measurements cannot be obtained using US pachymetry, measurements using anterior segment optical coherence tomography (OCT) may be used (with the measurement being between 700-900um)
• • 9. If applicable, prior corneal transplant ≥ 8 mm in diameter
• • 10. Adequate lid function and normal ocular surface and tear film parameters for implant of the study device, as determined by the investigator.
• Key Exclusion Criteria:
• * Patients who meet any of the following exclusion criteria cannot be consented and included in this study:
• • 1. Inability to provide written informed consent and comply with study assessments for the full duration of the study.
• • 2. Age: \< 18 years
• • 3. Patients who are pregnant/nursing or planning to become pregnant during the study.
• • Note: For women of child-bearing potential, confirmation of pregnancy status must be documented per site standard.
• • 4. Corneal thickness measurement (epithelium to endothelium; central and mid-peripheral/ 3 to 5mm away from center at superior, inferior, nasal and temporal quadrants) in the study eye with any measurement less than 700um or more than 900um measured using US pachymetry. If one or more measurements cannot be obtained using US pachymetry, measurements using anterior segment OCT may be used
• • 5. If applicable, prior corneal transplant \< 8 mm in diameter
• • 6. Aphakic or phakic status of the study eye
• • 7. Pseudophakic status of the study eye with anterior chamber IOL or unstable posterior chamber IOL, according to clinical history or UBM
• • 8. Evidence of tear film, ocular surface or lid abnormalities in the study eye
• • Schirmer test without anesthesia less than 5 mm at 5 minutes. NOTE: Patient can be eligible after successful tear duct blockage (such as plugs or cauterization) if the Schirmer's are adequate following the procedure
• • Evidence of conjunctival or lid margin keratinization
• • Presence of cicatrizing conjunctivitis (Stevens Johnson Syndrome, mucous membrane pemphigoid, trachoma, chemical, radiation or thermal trauma
• • Prior history of stage II or III neurotrophic keratitis / keratopathy
• • Limbal stem cell deficiency leading to prior episode(s) of recurrent or persistent corneal epithelial defects
• • Prior history of immune-mediated/ non-infectious keratolysis with or without underlying systemic disease
• • Significant lid margin disease with infestation/infection within 30 days prior to surgery.
• • NOTE: Patient can be eligible after successful treatment and resolution
• • Significant anatomical lid problems (trichiasis, entropion, ectropion, lagophthalmos, exophthalmos, Bell's palsy, or significant ptosis)
• • 9. Current or history of corneal or ocular surface infection in the study eye within 30 days prior to surgery.
• • NOTE: Patient can be eligible after successful treatment and resolution as determined by the investigator
• • 10. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, post-operative antibiotic or steroid drops , topical intraocular pressure lowering drops, allergy to sulfa drugs, or inability to tolerate oral intraocular pressure lowering drugs, or any component of the device
• • 11. History of ocular or periocular malignancy in the study eye within the previous five years
• • 12. Current or prior history of herpes simplex virus (HSV) or Varicella-zoster virus (VZV) keratitis in the study eye.
• • 13. History of shingles vaccination in the past year or intent to receive the vaccine during the study period
• • 14. Current or prior history of uveitis in the study eye
• • 15. Current or prior history of scleritis or retinitis in the study eye
• 16. Uncontrolled glaucoma defined by having one or both of the below:
• • Intraocular pressure of greater than 21 mm Hg
• • Intraocular pressure above the specific target pressure for the patient NOTE: Patients with history of glaucoma who are on topical glaucoma medications or who have undergone glaucoma surgery with intraocular pressure within the target range are eligible
• • 17. Hypotony in the study eye, as evidenced by an intraocular pressure of \< 6 mmHg
• 18. Presence of broad anterior synechia greater than a quadrant, defined by having both of the below:
• • 3 contiguous clock hours of synechia
• • Involving the central 8 mm of the cornea
• 19. Presence of significant corneal stromal vascularization, defined by having both of the below:
• • 3 contiguous clock hours of vascularization
• • Involving the central 8 mm of the cornea
• • 20. Retinal detachment within 30 days prior to surgery. NOTE: Patients with a prior history of retinal detachment surgery are eligible, unless they currently have silicone oil in the posterior segment
• • 21. Current (or prior) history of other keratoprosthesis device implantation
• • 22. Monocular status
• • 23. Inability to wear a soft contact lens due to conjunctival or lid abnormalities
• • 24. Signs of current (within the two weeks prior to surgery) systemic infection, including fever and current treatment with antibiotics
• • 25. Participation in another simultaneous interventional medical investigation or trial that may have a reasonable likelihood of affecting the outcomes of the present study
• • 26. Have any other history of clinically severe diseases, or conditions that in the opinion of the investigator, may affect the results of the study
• • 27. Any current or history of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication or adherence to study procedures
• • 28. Patients who are unable to comply with the study procedures and follow-up visits throughout the study period (12 months)